"We, at Mary Mediatrix Medical Center are committed to provide quality healthcare services to achieve optimum customer satisfaction across all our stakeholders and consistently respond to the need for continual improvement. To realize our commitment we shall: Deliver excellent and cost-effective services constantly; Adhere to our quality management system and applicable national and international statutory and regulatory requirements; Empower our members through awareness and trainings, teamwork and effective communication; Provide framework for setting our quality objectives and targets; and Evaluate our results towards institutional advancement and realization of our mission and vision."

During the past decade, Mary Mediatrix Medical Center conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 15 clinical trials were completed, i.e. on average, 115.4% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 9 clinical trials were completed. i.e. 225% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Mary Mediatrix Medical Center" #1 sponsor was "Pfizer" with 4 trials, followed by "Boehringer Ingelheim" with 3 trials sponsored, "EMD Serono" with 2 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored and "Hoffmann-La Roche" with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Mary Mediatrix Medical Center" #1 collaborator was "Incyte Corporation" with 2 trials as a collaborator, "Alfasigma S.p.A." with 1 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Mary Mediatrix Medical Center" are "Systemic Lupus Erythematosus" (4 trials), "Rheumatoid Arthritis" (3 trials), "Arthritis, Rheumatoid" (2 trials), "Lupus Erythematosus, Systemic" (2 trials) and "Lupus Nephritis" (2 trials). Many other conditions were trialed in "Mary Mediatrix Medical Center" in a lesser frequency.

Most popular intervention types in "Mary Mediatrix Medical Center" are "Drug" (17 trials), "Biological" (3 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Atacicept 150 mg" (2 trials), "Baricitinib" (2 trials), "CP-690,550" (2 trials) and "APL-2" (1 trials). Other intervention names were less common.

The vast majority of trials in "Mary Mediatrix Medical Center" are 19 trials for "All" genders.

Currently, there are NaN active trials in "Mary Mediatrix Medical Center". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in Mary Mediatrix Medical Center, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Mary Mediatrix Medical Center, 1 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 0 trials that are defined as “Not Applicable".